eCardio Diagnostics, a leader in remote arrhythmia monitoring services, has promoted John H. Untereker to President, effective immediately. He will remain COO.

Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Rhythmia™ Mapping System, a next-generation 3D mapping and navigation solution for use in cardiac catheter ablations and other electrophysiology (EP) procedures to diagnose or treat a variety of conditions in which the heart beats abnormally.

The June issue of Pharmaceuticals Monthly explores the delay in the approval of apixaban (Eliquis) by the FDA. “Apixaban shows how a review that seems, on its face, like it should be a quick and clean affair can become derailed by issues that, but for the agency’s own public disclosures post-approval, would never see the light of day,” according to the article.

Today, members of the Heart Rhythm Society (HRS) are visiting 35 congressional offices on Capitol Hill to raise visibility and support for two proposals: the “Medicare Program Integrity Improvement and Education Act” and the “Teaching Children to Save Lives Act.” HRS is advocating for the support of these two bills because both intend to deliver outcomes aligned with the Society’s mission to improve the care of patients by advancing research, education and optimal health care policies and standards. 

Vincent L. Gott, MD, professor emeritus at Johns Hopkins Heart & Vascular Institute in Baltimore, shares his experiences as a developer of the pacemaker in an interview with CNN. The feature is part of CNN’s “Life Works” series.

Hugh Calkins, MD, FHRS, CCDS, was named the president of the Heart Rhythm Society (HRS) during the 34th Annual Scientific Sessions, held in Denver last week.  Announced during the Presidents’ Reception on Friday, May 10th, Dr. Calkins now serves as the 35th president of HRS, making Anne M. Gillis, MD, FHRS, the immediate past president. Dr. Calkins is currently a Nicholas J. Fortuin Professor of Cardiology and Professor of Medicine at the Johns Hopkins University School of Medicine in Baltimore, Maryland.  

Seven percent of patients implanted with subcutaneous implantable cardioverter-defibrillators (S-ICDs) experienced inappropriate shocks, according to an analysis of registry data presented May 9 at the Heart Rhythm Society (HRS) scientific sessions in Denver.

The Watchman wait may be over. An analysis of long-term data found the Watchman left atrial appendage closure device to be superior to warfarin for primary efficacy and mortality.